Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ProfoundBio Closes $55 Million Round for ADC and IO Candidates

publication date: Jul 12, 2021

ProfoundBio, a Suzhou-Seattle oncology newco, closed a $55+ million Series A financing from China investors. The company will use the proceeds to advance its candidates from their ADC and immunoncology platforms into clinical trials. ProfoundBio's pipeline consists of eleven solid tumor-targeting drug candidates, currently in discovery and preclinical development. It plans to file several INDs next year. The round was led by Lilly Asia Venture and co-led by LYFE Capital, with participation from Sequoia Capital China and Oriza. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here